Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aquinox Pharmaceutic (AQXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,180
  • Shares Outstanding, K 23,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,000 K
  • 36-Month Beta -17.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.20 +8.92%
on 11/15/17
13.92 -20.19%
on 10/18/17
-2.78 (-20.01%)
since 10/17/17
3-Month
10.20 +8.92%
on 11/15/17
15.08 -26.33%
on 09/12/17
-3.37 (-23.27%)
since 08/17/17
52-Week
10.20 +8.92%
on 11/15/17
19.97 -44.37%
on 02/15/17
-3.54 (-24.16%)
since 11/17/16

Most Recent Stories

More News
Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today...

AQXP : 11.11 (+2.59%)
Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced...

AQXP : 11.11 (+2.59%)
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome

- Meeting to be Held December 7, 2017 -

AQXP : 11.11 (+2.59%)
Analyzing the Financial Health of Biotech Companies

LAS VEGAS, August 17, 2017 /PRNewswire/ --

AQXP : 11.11 (+2.59%)
BDSI : 2.25 (unch)
ZIOP : 4.57 (-3.59%)
PPCB : 0.0913 (+1.44%)
CPRX : 2.93 (+0.69%)
Analyzing the Financial Health of Biotech Companies

The business and technology behind the biotechnology industry is multifaceted and uncertain. This makes analyzing a biotech company's future success a challenging job. What makes this task even more difficult...

AQXP : 11.11 (+2.59%)
BDSI : 2.25 (unch)
PPCB : 0.0913 (+1.44%)
ZIOP : 4.57 (-3.59%)
CPRX : 2.93 (+0.69%)
Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results

- Enrollment in LEADERSHIP 301 with Rosiptor in IC/BPS Passes 50% -

AQXP : 11.11 (+2.59%)
Investor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 8:30...

AQXP : 11.11 (+2.59%)
Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced...

AQXP : 11.11 (+2.59%)
Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will...

AQXP : 11.11 (+2.59%)
Corium International (CORI) Catches Eye: Stock Jumps 11.9%

Corium International, Inc. (CORI) moved big last session, as the company saw its shares rise almost 12% on the day.

AQXP : 11.11 (+2.59%)
CORI : 11.43 (+6.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.

See More

Key Turning Points

2nd Resistance Point 11.66
1st Resistance Point 11.38
Last Price 11.11
1st Support Level 10.74
2nd Support Level 10.38

See More

52-Week High 19.97
Fibonacci 61.8% 16.24
Fibonacci 50% 15.08
Fibonacci 38.2% 13.93
Last Price 11.11
52-Week Low 10.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart